Does Repatha Help with Familial Hypercholesterolemia?
Yes, Repatha (evolocumab) lowers LDL cholesterol in patients with familial hypercholesterolemia (FH), a genetic condition causing high cholesterol from birth. Approved by the FDA for heterozygous FH (HeFH) in adults and children 10+ years old, and homozygous FH (HoFH) in adults, it reduces LDL-C by 50-70% when added to statins and other therapies.[1][2]
How Repatha Works for FH
Repatha is a PCSK9 inhibitor that binds to PCSK9 proteins in the blood, preventing them from breaking down LDL receptors on liver cells. This increases LDL receptor activity, clearing more LDL cholesterol from the bloodstream. In FH patients with defective receptors, it boosts the function of remaining receptors, providing additive LDL reduction beyond statins alone.[1][3]
Clinical Trial Results in FH Patients
Phase 3 trials like RUTHERFORD (HeFH) showed 59-66% LDL-C reduction at 12 weeks versus placebo. In HoFH (RUTHERFORD-2), it cut LDL-C by 21-31%, with some patients achieving over 50% drops when combined with apheresis. Long-term data from FOURIER confirmed sustained reductions and cardiovascular risk reduction.[2][4]
Who Qualifies and How It's Used
Prescribed for HeFH or HoFH patients whose LDL-C remains high (≥70 mg/dL clinical ASCVD, ≥100 mg/dL without) despite maximum-tolerated statins plus ezetimibe. Dosed as 140 mg every 2 weeks or 420 mg monthly via subcutaneous injection. Not first-line; used when oral therapies fail.[1][5]
What Happens If You Stop Repatha?
LDL-C rebounds to baseline within 2-4 weeks after stopping, as PCSK9 levels normalize. No withdrawal syndrome, but FH patients risk rapid cardiovascular progression without alternatives.[3]
Repatha vs. Other FH Treatments
Compared to statins (20-50% LDL reduction), Repatha adds 50-60% further drop. Versus competitor Praluent (alirocumab), similar efficacy (50-65% reduction) but Repatha has more HoFH data and pediatric approval. Apheresis for severe HoFH mechanically filters LDL but requires clinic visits; Repatha is self-administered at home.[2][6]
Common Side Effects FH Patients Report
Injection-site reactions (5-10%), nasopharyngitis, and upper respiratory infections occur most often. Rare allergic reactions or neurocognitive effects. Safe in pregnancy registries, but not recommended during pregnancy due to limited data.[1][5]
Cost and Access for FH Treatment
List price around $5,800/month (140 mg dose), but copay cards and patient assistance lower it to $0-25/month for eligible insured patients. Covered by most plans for FH with prior authorization.[7]
Patent Status and Generic Availability
Repatha patents expire in the US around 2034 (key composition patent US 8,030,457), with challenges from generics like Amgen's own biosimilar pipeline. No generics until then; track updates on DrugPatentWatch.com.8
[1]: Repatha Prescribing Information, Amgen (fda.gov)
[2]: FDA Approval Summary for Evolocumab (fda.gov)
[3]: PCSK9 Mechanism Review, NEJM (nejm.org)
[4]: RUTHERFORD-2 Trial, JAMA (jamanetwork.com)
[5]: FH Foundation Guidelines (thefhfoundation.org)
[6]: Praluent vs. Repatha Head-to-Head, Lancet (thelancet.com)
[7]: GoodRx Pricing Data (goodrx.com)